Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 18756.37 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-12-2020, the company reported a Standalone Total Income of Rs 736.50 Crore, up 4.99 % from last quarter Total Income of Rs 701.50 Crore and down -13.46 % from last year same quarter Total Income of Rs 851.10 Crore. Company reported net profit after tax of Rs 123.00 Crore in latest quarter.
Investment Rationale
Despite Covid-19 and Ankaleshwar divestiture, Sanofi posted a decent CY20 operational performance amid cost rationalisation measures, reduced marketing & promotional spends. Going ahead, the brokerage expects marketing spends to be lower than their historical trends on the back of higher adoption of digital marketing tools amid Covid-19. Sanofi remains one of the fastest growing companies in India in anti-diabetic therapy. It launched Toujeo within just three years of its launch in the US, which suggests it is prepared to launch core innovative products in India banking on growth prospects in the anti-diabetic category. A strong growth track in top brands, measured new launches (including innovative launches) besides strong balance sheet and comfort on corporate governance front are some key attributes of MNC pharma companies including Sanofi.
Promoter/FII Holdings
Promoters held 60.4 per cent stake in the company as of Dec 30, 2020, while FIIs held 11.5 per cent, DIIs 17.5 per cent and public and other 10.6 per cent.
